InvestorsHub Logo
Followers 417
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

Re: None

Saturday, 07/16/2016 11:28:41 AM

Saturday, July 16, 2016 11:28:41 AM

Post# of 284
*****AML Therapies: Seattle Genetics Vs. GlycoMimetics

ALSO JUNO MENTIONED

Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO


William Meyers
Follow (1,085 followers)

Long only, tech, biotech, research analyst


Summary


•Acute Myeloid Leukemia is very difficult to treat successfully.

•Seattle Genetics SGN-CD33A started a Phase 3 trial.

•GlycoMimetics GMI-1271 started Phase 2 trial.

•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.



http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SGEN News